Lenz Therapeutics Inc (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, stock fell 0.11% (As on March 25, 11:16:39 AM UTC-4, Source: Google Finance) after the company posted lower than expected results for the fourth quarter of FY 25. First commercial product sale of VIZZ in October 2025, the first and only aceclidine-based eye drop for the treatment of presbyopia. Q4 2025 product revenue of approximately $1.6 million, driven by over 20,000 filled prescriptions. On pace for over 45,000 paid prescriptions from launch through Q1 2026. In January 2026, launched the “Make it VIZZable” direct-to-consumer (“DTC”) campaign featuring Sarah Jessica Parker across omni-channel digital platforms, supported by national television appearances on Good Morning America, The Today Show and Jimmy Kimmel Live. Strong initial consumer engagement, with VIZZ.com website traffic increasing as much as 10x following national media activations. The Company plans to continue its digital campaign and expand into network television advertising in select markets in early Q2 2026. Cash, cash equivalents and marketable securities were $292.3 million as of December 31, 2025, which is anticipated to fund operations to post-launch positive operating cash flow.
Moreover, in March 2026, LENZ submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for VIZZ for the treatment of presbyopia. This submission represents the fifth ex-U.S. regulatory filing for VIZZ. Additional recent NDA submissions include Thailand and Singapore in Q1 2026, in addition to South Korea in Q4 2025 and China in Q3 2025. In January 2026, LENZ announced an exclusive commercialization partnership with Lunatus for the Middle East. Under the terms of the agreement, LENZ will receive upfront payments, regulatory and commercial milestones, and a significant share of regional revenue through a pre-determined minimum product supply price. This agreement represents the Company’s fourth ex-U.S. commercialization partnership for VIZZ.
LENZ in the fourth quarter of FY 25 has reported the adjusted loss per share of $1.16, missing the analysts’ estimates for the adjusted loss per share of $0.91. The company had reported the adjusted revenue of $1.59 million in the fourth quarter of FY 25, missing the analysts’ estimates for revenue by 66.75%. License revenue was zero and $17.5 million for the fourth quarter and year ended December 31, 2025.
To support growing demand and broad prescriber base, LENZ is expanding its sales organization from 88 to 117 territories, increasing the frequency and reach of ECP engagement. The expanded sales force is expected to be fully deployed in Q2 2026.